tiprankstipranks
CareDx downgraded to Hold at Craig-Hallum after Medicare ‘worst case scenario’
The Fly

CareDx downgraded to Hold at Craig-Hallum after Medicare ‘worst case scenario’

As previously reported, Craig-Hallum analyst Alexander Nowak downgraded CareDx to Hold from Buy with a price target of $9, down from $26, arguing that the "worst-case scenario just occurred" with Palmetto MolDx announcing an update to its Billing and Coding ruleset for the umbrella coverage determination that "dramatically changes reimbursement for transplant testing." The policy appears to eliminate HeartCare reimbursement and "make KidneyCare reimbursement a non-starter," while it also "dramatically weakens" reimbursement for kidney transplant testing when used in the surveillance setting, the analyst tells investors. The firm estimates that at least $15M of revenue is from HeartCare, specifically the AlloSure Heart component, and this "will be reduced to $0."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on CDNA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles